The Oklahoma Medical Research Foundation has received a $3 million grant to study Parkinson's disease, potentially leading to ...

Parkinson’s patients and their caregivers attended the first “Parkinson’s Today:  An Educational Symposium” in Palm Desert on Saturday.  PRO or Parkinson’s Resource Organization teamed up with The ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.

Samsung is recognizing Española Valley High School for its student’s efforts to help people dealing with Parkinson’s Disease. Students, in coordination with ...

The U.S. Food and Drug Administration (FDA) has approved Onapgo (apomorphine hydrochloride) injection, the first and only ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...

A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients. Serina Therapeutics, based ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...